Stock listing
NYSE American:OSTX OS Therapies Incorporated Stock
Home listing (NYSE American) of OS Therapies Incorporated
Follow OS Therapies Incorporated into a list and get an email when it puts out news.
Share price · AMEX:OSTX
$1.15 USD -0.09 (-7.3%)
Close on Nov 2, 2026
- Day range
- $1.12 – $1.30 USDNov 2, 2026
- Volume
- 928,981 sharesNov 2, 2026
- Market cap
- $53.83M USDAt the close on Nov 2, 2026 · price × 46.81M shares outstanding
- 52-week range
- $1.12 – $2.25 USDLowest and highest trades, Nov 3, 2025 – Nov 2, 2026
- Traded on an average day
- $946,804 USDMedian day 393,179 shares · last 3 months, Aug 3, 2026 – Nov 2, 2026
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NYSE American:OSTX · Home | $1.15 USD | -0.09 (-7.3%) | 928,981 | $1.24 | $1.30 | $1.115 | $1.24 | Close on Nov 2, 2026 |
Daily closes
Last 3 months, Aug 3, 2026 – Nov 2, 2026 · AMEX:OSTX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.15 | -0.09 | -7.3% | $1.24 | $1.30 | $1.115 | 928,981 | |
| $1.24 | -0.06 | -4.6% | $1.27 | $1.28 | $1.21 | 321,618 | |
| $1.30 | +0.05 | +4.0% | $1.25 | $1.33 | $1.25 | 388,780 | |
| $1.25 | +0.02 | +1.6% | $1.24 | $1.28 | $1.22 | 273,881 | |
| $1.23 | +0.02 | +1.7% | $1.22 | $1.28 | $1.20 | 318,053 | |
| $1.21 | -0.04 | -3.2% | $1.27 | $1.27 | $1.20 | 247,655 | |
| $1.25 | 0.00 | 0.0% | $1.27 | $1.29 | $1.23 | 142,121 | |
| $1.25 | -0.02 | -1.6% | $1.27 | $1.31 | $1.24 | 344,358 | |
| $1.27 | +0.01 | +0.8% | $1.27 | $1.33 | $1.25 | 338,045 | |
| $1.26 | -0.01 | -0.8% | $1.30 | $1.34 | $1.255 | 320,657 | |
| $1.27 | -0.05 | -3.8% | $1.33 | $1.34 | $1.23 | 704,744 | |
| $1.32 | -0.09 | -6.4% | $1.42 | $1.43 | $1.30 | 529,171 | |
| $1.41 | +0.02 | +1.4% | $1.38 | $1.44 | $1.375 | 375,237 | |
| $1.39 | -0.06 | -4.1% | $1.45 | $1.48 | $1.38 | 497,347 | |
| $1.45 | -0.11 | -7.1% | $1.57 | $1.58 | $1.45 | 810,557 | |
| $1.56 | -0.06 | -3.7% | $1.61 | $1.623 | $1.56 | 247,344 | |
| $1.62 | 0.00 | 0.0% | $1.62 | $1.66 | $1.59 | 422,126 | |
| $1.62 | +0.07 | +4.5% | $1.55 | $1.68 | $1.54 | 664,816 | |
| $1.55 | +0.06 | +4.0% | $1.50 | $1.565 | $1.464 | 586,742 | |
| $1.49 | -0.11 | -6.9% | $1.71 | $1.74 | $1.47 | 6,015,385 | |
| $1.60 | -0.02 | -1.2% | $1.61 | $1.63 | $1.565 | 416,202 | |
| $1.62 | +0.01 | +0.6% | $1.625 | $1.66 | $1.62 | 233,394 | |
| $1.61 | +0.01 | +0.6% | $1.62 | $1.65 | $1.56 | 329,638 | |
| $1.60 | -0.01 | -0.6% | $1.60 | $1.67 | $1.59 | 475,091 | |
| $1.61 | -0.04 | -2.4% | $1.64 | $1.66 | $1.60 | 549,523 | |
| $1.65 | -0.01 | -0.6% | $1.66 | $1.679 | $1.61 | 353,424 | |
| $1.66 | 0.00 | 0.0% | $1.67 | $1.68 | $1.64 | 171,423 | |
| $1.66 | +0.01 | +0.6% | $1.66 | $1.67 | $1.615 | 347,757 | |
| $1.65 | -0.12 | -6.8% | $1.76 | $1.77 | $1.64 | 654,500 | |
| $1.77 | +0.03 | +1.7% | $1.76 | $1.84 | $1.74 | 600,390 | |
| $1.74 | -0.03 | -1.7% | $1.81 | $1.815 | $1.74 | 637,059 | |
| $1.77 | -0.06 | -3.3% | $1.81 | $1.83 | $1.76 | 908,579 | |
| $1.83 | +0.08 | +4.6% | $1.80 | $2.00 | $1.80 | 2,230,933 | |
| $1.75 | -0.03 | -1.7% | $1.79 | $1.82 | $1.74 | 421,327 | |
| $1.78 | +0.08 | +4.7% | $1.78 | $1.81 | $1.71 | 1,054,087 | |
| $1.70 | +0.02 | +1.2% | $1.65 | $1.79 | $1.62 | 993,722 | |
| $1.68 | -0.14 | -7.7% | $1.81 | $1.84 | $1.66 | 825,871 | |
| $1.82 | -0.04 | -2.2% | $1.87 | $1.92 | $1.81 | 547,914 | |
| $1.86 | +0.03 | +1.6% | $1.83 | $1.92 | $1.80 | 393,179 | |
| $1.83 | -0.05 | -2.7% | $1.96 | $2.015 | $1.75 | 1,767,807 | |
| $1.88 | +0.06 | +3.3% | $1.84 | $1.96 | $1.84 | 982,579 | |
| $1.82 | +0.11 | +6.4% | $1.72 | $1.84 | $1.72 | 894,277 | |
| $1.71 | +0.05 | +3.0% | $1.68 | $1.72 | $1.61 | 530,467 | |
| $1.66 | -0.03 | -1.8% | $1.68 | $1.705 | $1.63 | 400,615 | |
| $1.69 | +0.05 | +3.0% | $1.62 | $1.69 | $1.62 | 234,957 | |
| $1.64 | -0.04 | -2.4% | $1.69 | $1.69 | $1.60 | 294,984 | |
| $1.68 | +0.03 | +1.8% | $1.65 | $1.72 | $1.641 | 518,150 | |
| $1.65 | 0.00 | 0.0% | $1.65 | $1.65 | $1.60 | 351,463 | |
| $1.65 | +0.10 | +6.5% | $1.53 | $1.65 | $1.53 | 351,233 | |
| $1.55 | -0.04 | -2.5% | $1.50 | $1.55 | $1.46 | 438,883 | |
| $1.59 | +0.01 | +0.6% | $1.56 | $1.635 | $1.56 | 386,419 | |
| $1.58 | +0.12 | +8.2% | $1.50 | $1.58 | $1.45 | 369,640 | |
| $1.46 | +0.02 | +1.4% | $1.46 | $1.47 | $1.40 | 283,642 | |
| $1.44 | -0.03 | -2.0% | $1.48 | $1.51 | $1.43 | 231,505 | |
| $1.47 | -0.15 | -9.3% | $1.59 | $1.59 | $1.44 | 1,152,498 | |
| $1.62 | +0.02 | +1.3% | $1.58 | $1.63 | $1.56 | 401,744 | |
| $1.60 | -0.01 | -0.6% | $1.59 | $1.61 | $1.54 | 573,387 | |
| $1.61 | +0.01 | +0.6% | $1.62 | $1.63 | $1.58 | 225,070 | |
| $1.60 | -0.03 | -1.8% | $1.61 | $1.626 | $1.58 | 132,982 | |
| $1.63 | +0.03 | +1.9% | $1.61 | $1.64 | $1.59 | 175,463 | |
| $1.60 | -0.03 | -1.8% | $1.63 | $1.65 | $1.58 | 289,417 | |
| $1.63 | +0.03 | +1.9% | $1.59 | $1.65 | $1.59 | 223,972 | |
| $1.60 | -0.03 | -1.8% | $1.63 | $1.64 | $1.58 | 243,633 | |
| $1.63 | +0.08 | +5.2% | $1.55 | $1.64 | $1.55 | 348,855 | |
| $1.55 | +0.03 | +2.0% | $1.53 | $1.58 | $1.52 | 214,291 |
- Ticker
- NYSE American:OSTX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NYSE American
- Currency
- USD
What changed lately
Latest news release · Oct 1, 2026
OS Therapies Appoints Kerry Clem as Chief Commercial Officer and Frank Knuettel II as Chief Financial Officer
Latest deck · September 2026
Investor Presentation (September 2026)
Investor deck · 19 slides
Latest news
OS Therapies Appoints Kerry Clem as Chief Commercial Officer and Frank Knuettel II as Chief Financial Officer
Oct 1, 2026
Closed $1.61 (+0.6%) on Oct 1, 2026
OS Therapies Announces Brand Name 'Herlystic' Approved by World Health Organization for OST-HER2 (daznelimgene lisbac)
Sep 24, 2026
Closed $1.66 (+0.6%) on Sep 24, 2026
OS Therapies Completes FDA Type C Statistical Methods Meeting and Provides Update on Global Regulatory Coordination for OST-HER2 Under Project Orbis
Sep 21, 2026
Closed $1.74 (-1.7%) on Sep 21, 2026
OS Therapies Achieves Incremental Alignment With FDA and Accepts Project Orbis Invitation From MHRA on OST-HER2 Metastatic Osteosarcoma Program
Sep 17, 2026
Closed $1.83 (+4.6%) on Sep 17, 2026
OS Therapies Announces Full Alignment with UK MHRA and EU EMA for Conditional Marketing Authorisation Application Filing
Sep 15, 2026
Closed $1.78 (+4.7%) on Sep 15, 2026
OS Therapies Achieves Statistically Significant Benefit for OST-HER2-Treated Patients in Interim 3-Year Overall Survival Analysis of Phase 2b Pulmonary Metastatic Osteosarcoma Trial
Sep 8, 2026
Closed $1.83 (-2.7%) on Sep 8, 2026
OS Therapies Provides OST-HER2 Metastatic Osteosarcoma Program Update and Announces Upcoming Conference Attendance
Sep 2, 2026
Closed $1.71 (+3.0%) on Sep 2, 2026
OS Therapies Reports Second Quarter 2026 Financials and Provides Business and Regulatory Updates
Aug 17, 2026
Closed $1.47 (-9.3%) on Aug 17, 2026
OS Therapies Granted U.S. FDA Type C Statistical Methods Meeting to Review 2.5-Year Overall Survival Data for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic Osteosarcoma
Aug 13, 2026
Closed $1.60 (-0.6%) on Aug 13, 2026
OS Therapies Accepts New FDA Meeting Request to Review Biomarker Data as Part of BEST Program
Jul 8, 2026
Closed $1.46 (-8.2%) on Jul 8, 2026
Financings
Debt financing
Aug 17, 2026
Tranche closed: US$5M raised
Decks
Investor Presentation (September 2026)
Investor deck · 19 slides · September 2026
Biomarker-focused Conference Call (April 2026)
Conference · 35 slides · Apr 30, 2026
Investor Presentation (October 2025)
Investor deck · 28 slides · Oct 17, 2025
OS Therapies Incorporated on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 43 in the last 12 months · 72 in all · newest Oct 1, 2026 · oldest 2025
- Decks
- 3 decks · latest September 2026
Where OS Therapies Incorporated is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NYSE American:OSTX · Home listing · This page | NYSE American | United States | USD |
| BOATS:OSTX | BOATS | United States | USD |
Log in to ask 6ix AI your own questions about OS Therapies Incorporated.